DOTA-(Tyr3)-Octreotate manufacturers
- DOTA-(Tyr3)-Octreotete
-
-
2026-09-11
- CAS:177943-89-4
- Min. Order: 1mg
- Purity: ≥95% or 98%
- Supply Ability: 1kg/month
|
| | DOTA-(Tyr3)-Octreotate Basic information |
| Product Name: | DOTA-(Tyr3)-Octreotate | | Synonyms: | 4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OH, (DISULFIDE BOND) ACETATE;DOTA-(TYR3)-OCTREOTATE ACETATE;DOTA-(TYR3,THR8)-OCTREOTIDE ACETATE;DOTA-(Tyr3)-Octreotete;N-[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threonine cyclic (2-7)-disulfide acetate (salt);L-Threonine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-Dphenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2)-disulfide, acetate (salt) (9CI);DOTA-(Tyr3)-Octreotate acetate salt 4,7,10-Tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH acetate salt (Disulfide bond);S-2-(4-Isothiocyanatobenzyl)-1, 4, 7, 10-tetraaza-1, 4, 7, 10-tetra(2-carbamoylmethyl)cyclododecane | | CAS: | 177943-89-4 | | MF: | C67H94N14O21S2 | | MW: | 1495.69 | | EINECS: | | | Product Categories: | | | Mol File: | 177943-89-4.mol |  |
| | DOTA-(Tyr3)-Octreotate Chemical Properties |
| storage temp. | Store at -20°C, protect from light, stored under nitrogen | | solubility | PBS (pH 7.2): Slightly Soluble: 0.1-1 mg/ml | | form | Solid | | color | White to off-white | | InChIKey | MGIRFLMPSDEBOD-MGZWADLVNA-N |
| | DOTA-(Tyr3)-Octreotate Usage And Synthesis |
| Chemical Properties | Colourless to off-white lyophilised solid | | Uses | DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT)[1][2][3][4]. DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs). | | in vivo | 177Lu-DOTATATE shows excellent antitumor effects in rats[1]. | | IC 50 | RDC Peptide | | References | [1] Jong M, et, al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. PMID:15653647
[2] Gains JE, et, al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10. DOI:10.1097/MNM.0000000000001265
[3] Breeman WAP, et, al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. DOI:10.1007/s00259-003-1142-0
[4] Reubi JC, et, al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82. DOI:10.1007/s002590050034
[5] MELPOMENI FANI Damian W Guillaume P Nicolas. Somatostatin Receptor Antagonists for Imaging and Therapy.[J]. Journal of Nuclear Medicine, 2017, 58 Suppl 2: 61S-66S. DOI: 10.2967/jnumed.116.186783 |
| | DOTA-(Tyr3)-Octreotate Preparation Products And Raw materials |
|